Lilly Expects Alimta Advisory Committee Review For Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is considering the pemetrexed sNDA for a July 27 Oncologic Drugs Advisory Committee meeting. First quarter sales of Alimta were $12 mil., including $7 mil. in initial stocking for the mesothelioma agent.
You may also be interested in...
Lilly Alimta To Be Available In Two Weeks Following Five-Month Review
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.